Business

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

Financial Post · October 22, 2026 at 7:13 a.m.

MDNA209 is a potential first-in-class engineered Superkine designed to block CD122 and simultaneously inhibit IL-2 and IL-15 signaling to modulate an overactive immune system TORONTO and HOUSTON, Oct.

22, 2026 (GLOBE NEW

Read the full article on Financial Post ›

5News aggregated this summary from the outlet’s public feed. The full article, with all the context, is on financialpost.com — the content belongs to Financial Post.

Medicenna to Present Preclinical Data on Its CD122 Superantagonist MDNA209 at The Promises of Treg and Interleukin-2 Therapies Conference

More from Financial Post

Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development

SalesCloser Files New U.S. Patent Application Covering Dynamic Multi-Agent Participation and Orchestration in Live Calls

CI Global Asset Management Announces Monthly Cash Distributions for October 2026 for Certain CI ETFs

Can Eight Years Change Your Mind? Samsung Canada Invites Canadians to Revisit Their First Impressions of Foldables

More in Business

Boehringer Ingelheim and Microsoft partner to drive patient-centric and AI-backed clinical development

SalesCloser Files New U.S. Patent Application Covering Dynamic Multi-Agent Participation and Orchestration in Live Calls

CI Global Asset Management Announces Monthly Cash Distributions for October 2026 for Certain CI ETFs

Can Eight Years Change Your Mind? Samsung Canada Invites Canadians to Revisit Their First Impressions of Foldables

Canopy Growth to Report Second Quarter Fiscal 2027 Financial Results on November 6, 2026

Ontario SPCA Receives $200K Companions for Change™ Sponsorship for Litter, Treats and Toys